UNIVERSITY OF SOUTH FLORIDA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1956-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.usf.edu
Clinical Trials
319
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (249 trials with phase data)• Click on a phase to view related trials
FRESH-EATS Project
- Conditions
- Dietary BehaviorsObesity and Overweight
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 48
- Registration Number
- NCT07053644
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
Postbiotics for Mitigation of Postoperative Dysbiosis in Colon Cancer Surgery
- Conditions
- Colon Cancer
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 30
- Registration Number
- NCT07050485
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸University of South Florida, Tampa, Florida, United States
Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD
- Conditions
- Inflammatory Bowel Diseases
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 15
- Registration Number
- NCT07017959
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
Breaking Fasts Ahead of Cardiac Caths
- Conditions
- Stable Angina (SA)Unstable Angina (UA)NSTEMI - Non-ST Segment Elevation MI
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 400
- Registration Number
- NCT06996639
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds
- Conditions
- Colorectal CancerSarcomaBrain TumorsEndometrial CancerOvarian Cancer
- Interventions
- Other: No InterventionsDietary Supplement: Sports Pro Resolve 4 gDietary Supplement: Double Wood SPM 4 gDietary Supplement: 20 California Sweet AlmondsCombination Product: Montelukast 10 Mg Oral Tablet and SPM 4 gDietary Supplement: Cold- Pressed Almond Oil 30 mL
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 56
- Registration Number
- NCT06887673
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸University of South Florida, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 62
- Next
News
NeuroEM Therapeutics Secures $1.33 Million in Series A Funding to Advance Drug-Free Alzheimer's Treatment
NeuroEM Therapeutics has closed initial rounds totaling $1.33 million of a $5 million Series A equity raise led by BlueLake.vc to commercialize its Transcranial Electromagnetic Treatment (TEMT-RF) technology.
Amneal's CREXONT Shows Significant Sleep Quality Improvements in Parkinson's Disease Patients
New Phase 3 RISE-PD study data reveals CREXONT (carbidopa/levodopa extended-release) significantly improved sleep quality in Parkinson's disease patients compared to immediate-release formulations, with a mean difference of -2.35 in PDSS-2 scores (p<0.0001).
Dupilumab Shows Strong Efficacy in Chronic Spontaneous Urticaria Across All BMI Ranges
Phase 3 LIBERTY-CSU CUPID trials demonstrate dupilumab's effectiveness in reducing itch and urticaria activity in patients unresponsive to H1-antihistamines.
North American Hospitals Spearhead Clinical Trials for Trigeminal Neuralgia
Leading hospitals across North America are actively engaged in clinical trials to find effective treatments for trigeminal neuralgia, a condition causing severe facial pain.